BioCentury
ARTICLE | Company News

Roche returns rights to Chugai for diabetes candidate

July 5, 2011 11:54 PM UTC

Roche (SIX:ROG; OTCQX:RHHBY) returned ex-Japanese rights to diabetes candidate CSG452 to Chugai Pharmaceutical Co. Ltd. (Tokyo:4519). Roche, which gained the product through a 2007 deal, made the decision after reviewing the priority of its development pipeline, according to Chugai. The sodium-glucose cotransporter 2 (SGLT2) inhibitor is in Phase III testing in Japan for Type II diabetes, with a regulatory submission planned for 2013. Chugai said it will seek a new partner for development of CSG452 elsewhere. Chugai is majority owned by Roche. ...